Clinical Trials Browser

Phase 2 × OTHER × Gefitinib × Clear all

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

Neoplasm Metastasis, Osteosarcoma

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Lung Neoplasms

NCT02347839 2024-12-10

NEGOTIATE

Phase 2 Withdrawn

Lung Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT00198380 2024-03-08

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Phase 2 Completed

Adenocarcinoma, Bronchiolo-Alveolar

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT00483561 2023-09-13

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

26 enrolled 7 charts

Prostatic Neoplasms

NCT01833572 2023-07-12

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Phase 2 Completed

70 enrolled 11 charts

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT02447419 2022-06-15

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT02804776 2021-06-02

PROGRESS

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02025218 2021-04-01

IRENE

Phase 2 Terminated

Lung Neoplasms

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

Lung Neoplasms

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01933347 2020-02-06

Third-line Treatment of Gefitinib in NSCLC Patients

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00014183 2019-11-07

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00282100 2019-04-16

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Liver Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT00493025 2018-12-06

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Phase 2 Terminated

19 enrolled 4 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT00025675 2018-06-26

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT01864681 2018-06-20

CGMT

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2 Unknown

Gastrointestinal

Gallbladder Neoplasms

NCT03399669 2018-01-16

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00509002 2017-11-24

Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed

37 enrolled 4 charts

Salivary Gland Neoplasms

NCT00206492 2017-08-01

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Phase 2 Terminated

Breast Neoplasms, Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT01310855 2017-05-31

Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Phase 2 Terminated

38 enrolled 8 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01965275 2017-05-08

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Phase 2 Unknown

Drug-Related Side Effects and Adverse Reactions

NCT03123484 2017-04-21

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase 2 Completed

Lung Neoplasms

NCT00231465 2017-03-03

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT03002844 2016-12-28

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00062062 2016-12-14

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00100945 2016-12-13

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT02787447 2016-11-25

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Phase 2 Unknown

Adenocarcinoma of Lung

NCT02951637 2016-11-01

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Phase 2 Unknown

Adenocarcinoma of Lung, Adenocarcinoma

NCT02930954 2016-10-13

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00519077 2016-07-01

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT02788058 2016-06-02

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Phase 2 Unknown

Adenocarcinoma of Lung

NCT01783834 2016-02-11

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Phase 2 Completed

Previous Treated Metastatic Non-small Cell Lung Cancer

NCT00588445 2016-01-22

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Phase 2 Completed

65 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00177242 2016-01-18

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Phase 2 Completed

Neoplasms

NCT00268346 2016-01-05

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Phase 2 Completed

58 enrolled 6 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT00986284 2015-12-22

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

NCT00479089 2015-11-02

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

Phase 2 Terminated

50 enrolled 5 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00258323 2015-09-30

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms